Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF

Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF hamster model at the Keystone conference

Physiogenex will attend 28th APASL meeting in Manila, Philippines

HFpEF: Should We Consider Diabetic Patients Separately?: The

Frontiers Heart Failure Syndrome With Preserved Ejection

Natália Breyner - Scientist/Project Manager/R&D at Physiogenex

Liraglutide shows superior cardiometabolic benefits than

Frontiers Rationale for the Use of Pirfenidone in Heart Failure

Physiogenex on LinkedIn: Physiogenex is at ILC-EASL 2022 in London

نشر Rana Assaly على LinkedIn

François Briand på LinkedIn: #era2022 #era2022 #louvre #obesity

Immunometabolic mechanisms of heart failure with preserved

Physiogenex on LinkedIn: Physiogenex is at ILC-EASL 2022 in London